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Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against
gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucle-
otide metabolic enzymes, and efﬂux transporters have been reported to be involved in gemcitabine resis-
tance. Althoughmost of the resistant factors are supposed to be related to each other, it is unclear how one
factor can affect the other one. In this study, we established gemcitabine-resistant pancreatic cancer cell
lines. Gemcitabine resistance in these cells is caused by two major processes: a decrease in gemcitabine
uptake and overexpression of ribonucleotide reductase large subunit (RRM1). Knockdown of RRM1, but not
the overexpression of concentrative nucleoside transporter 1 (CNT1), could completely overcome the
gemcitabine resistance. RRM1 knockdown in gemcitabine-resistant cells could increase the intracellular
accumulation of gemcitabine by increasing the nucleoside transporter expression. Furthermore, a syner-
gistic effectwas observed between hydroxyurea, a ribonucleotide reductase (RR) inhibitor, and gemcitabine
on thegemcitabine-resistant cells.Herewe indicate that RR is oneof themostpromising targets toovercome
gemcitabine resistance in gemcitabine-resistant cells with dual resistant factors.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ncology and Center for the Research of Advanced Diagnosis and Therapy of Cancer, Graduate School of Medical and
gaoka, Kagoshima 890-8544, Japan. Tel.: þ81 99 275 5490; fax: þ81 99 265 9687.
ac.jp (T. Furukawa).
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Pancreatic cancer is one of themost difﬁcultmalignancies to treat
successfully. Only 15%e20% of patients are eligible for a potentially
curative resection at the diagnosis. Even if surgical resection is per-
formed, the recurrence rate is high and the survival rate after surgery
is poor (1). Therefore, effective chemotherapy is indispensable to
improve the prognosis of patients with pancreatic cancer.
Gemcitabine (20,20-diﬂuoro deoxycytidine) is used for the
treatment of not only pancreatic cancer but also lung and bladder
cancers. However, the occurrence of drug-resistant cells greatly
hinders successful cancer therapy. Gemcitabine is a unique anti-
metabolite in that its metabolites dFdCDP and dFdCTP can inhibit
ribonucleotide reductase (RR) by binding to ribonucleotide reduc-
tase large subunit (RRM1) and can terminate DNA elongation pro-
cesses by incorporating into DNA, respectively (2).
Multiple factors, including the attenuation of nucleoside trans-
porters, the expression change of gemcitabine-activating or
-degradation enzymes and target molecules, and the expression of
efﬂux transporters, have been reported to cause gemcitabine
resistance (3e14).
However, the relationship between each factor is not clear,
although several of these factors are thought to inﬂuence each
other in gemcitabine metabolism. This relationship needs to be
elucidated to ﬁnd a good strategy to overcome gemcitabine resis-
tance. Therefore, we established gemcitabine-resistant cell lines
from a pancreatic cancer cell line, MIA PaCa-2, and systematically
examined the mechanisms underlying the gemcitabine resistance
of the cells.
2. Materials and methods
2.1. Cells
The human pancreatic cancer cell line MIA PaCa-2 was provided
by the Riken BioResource Center, Japan. MIA PaCa-2 cells were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM; Nissui
Seiyaku, Tokyo, Japan), containing 10% fetal calf serum (FCS; PAA
Laboratories, Pasching, Austria), at 37 C in an atmosphere con-
taining 5% CO2.
MGEM6 cells were transfected with pDNA3.1-hCNT1 using
electroporation (Gene Pulser, Bio Rad). The cells were selected with
G418 and MGEM6/CNT1#17 cells were used for further analysis.
MGEM6 and MGEM6/CNT1#17 cells were transfected with pLKO.1-
shRRM1 (SigmaeAldrich Corp., St. Louis, MO, USA) as described
above. The cells were selected by puromycin and MGEM6/KD5-6
and MGEM6/CNT1#17KD5-7 cells were used for further analysis.
2.2. Plasmids
The concentrative nucleoside transporter 1 (CNT1) plasmid
pDNA3.1-hCNT1is described elsewhere (15). Mission shRNA
expression plasmids against RRM1 mRNA (NM_001033_2471S)
were purchased from SigmaeAldrich Corp. (St. Louis, MO, USA).
2.3. Chemicals, anticancer agents, and antibodies
DMEMwas purchased fromNissui Seiyaku (Tokyo, Japan), FCSwas
purchased from PAA Laboratories (Pasching, Austria), (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), G418,
puromycin, cytosine arabinoside (Ara-C), 2-chlorodeoxyadenosine
(cladribine), N-methyl-D-glucamine, nitrobenzylthioinosine (NBTI),
dipyridamole, and hydroxyurea (HU) were purchased from Sigma-
eAldrichCorp (St. Louis,MO,USA), p-amidinophenylmethanesulfonyl
ﬂuoride (p-APMSF)waspurchased fromWako (Osaka, Japan), and [3H]gemcitabine was purchased from Moravek Biochemicals and Radio-
chemicals (Brea, CA, USA).
Gemcitabine was obtained as a gift from Ely Lilly and Co. Anti-
hCNT1 was generated as described previously (16). Other anti-
bodies were purchased from the indicated companies: hENT1
(Abgent, San Diego, CA, USA: AP1086c), hENT2 (Abcam, Cambridge,
UK: ab48595), RRM1 (Cell Signaling Technology, Danvers, MA, USA:
#3388), RRM2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA:
sc10846), p53R2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA:
sc10840), GAPDH (Cell Signaling Technology, Danvers, MA, USA)
sodium/potassium-transporting ATPase a3 (Naþ/Kþ ATPase a3)
(Abcam, MA, USA, XVIF9-G10).
2.4. Cell viability assay
The sensitivity to the anticancer agents was determined by the
MTT assay using 96-well plates seeded 5  103 cells/well as
described previously (17). The IC50 was determined as the con-
centration of the agents that reduced the number of cells to 50% of
that of cells cultured in control medium.
2.5. Gemcitabine accumulation under normal and inhibitory
conditions with nucleoside transporters
To measure the gemcitabine accumulation, subconﬂuent cells
cultured in 12-well plates were incubated with 1 mM hot (3[H]-
labeled) and cold gemcitabine in the medium at 37 C for 1 h. After
removal of the media, the cells were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed with 0.5 mL ice-cold PBS
containing 1% Triton X-100 and 0.2% sodium dodecyl sulfate (SDS).
Five milliliters scintillation solution was added to the lysate and the
radioactivity was measured with a liquid scintillation counter (18).
For the prewash and the 1-hr incubation with gemcitabine un-
der inhibitory conditions for one or more nucleoside transporter(s),
we used 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)-buffered Ringer's solution for the control conditions,
consisting of 135 mM NaCl, 5 mM KCl, 3.33 mM NaH2PO4, 0.83 mM
Na2HPO4, 1.0 mM CaCl2, 1.0 mM MgCl2, 10 mM glucose, and 5 mM
HEPES (pH 7.4); Na-free buffer for the CNT1 inhibition condition,
containing 140 mM N-methyl-D-glucamine, 5 mM HEPES, 5 mM
KH2PO4, 1.0 mM CaCl2, 1.0 mMMgCl2, and 10 mM glucose (pH 7.4);
Na-free buffer containing 100 nM NBTI for the CNT1 and ENT1in-
hibition condition; and Na-free buffer containing 10 mM dipyr-
idamole for the CNT1, equilibrative nucleoside transporter 1
(ENT1), and ENT2 inhibition condition (19).
To determine the efﬂux rate of gemcitabine from the cells,
subconﬂuent cells cultured in 12-well plates were incubated with
1 mM hot and cold gemcitabine in DMEM, containing 10% FCS, at
37 C for 1 h, andwerewashedwith PBS at 37 C. After adding fresh,
warm medium without gemcitabine until each indicated time, the
cells were washed and solubilized. The radioactivity of the lysates
was determined as described above.
2.6. Cell fractionation and immunoblotting
Cell membrane fractions were isolated as described previously
(17). Total cell lysate was isolated from the cells with lysis buffer
(50 mM TriseHCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1%
aprotinin, and 1 mM p-APMSF). After lysis, the cell debris was
removed by centrifugation at 14,000 g for 15 min at 4 C.
Immunoblotting was performed as described previously (17)
and the blotted membranes were developed using the enhanced
chemiluminescence immunoblotting detection system (GE
healthcare Bio-Sciences, Piscataway, NJ, USA) and were exposed to
X-ray ﬁlm. The chemiluminescence intensities of the bands were
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Leandro, CA) and the normalized numbers by the intensity of
respective loading control Naþ/Kþ ATPase a3 for Figs. 2A and 3E or
GAPDH for Fig. 3A were indicated.
2.7. Reverse transcription PCR
Total RNA from the cultured cells was isolated using TRIzol (Life
Science Technology, Carlsbad, CA, USA), and RNA (2 mg) was
reverse-transcribed using a ReverTra Ace kit (Toyobo, Osaka, Japan),
according to the manufacturer's instructions.
2.8. Quantitative reverse transcription PCR
Quantitative reverse transcription PCR was performed as
described previously (20). The respective forward and reverse
primers' sequences are provided in Supplementary Table 1.
2.9. Analysis of synergistic effects
To evaluate a potential synergistic effect between hydroxyurea
(HU) and gemcitabine, we used the median effect analysis method
of Chou and Talalay (21). Molar ratios of gemcitabine and HU in the
evaluationwere determined as 1:25000 and 1:200with IC50 of each
agent to MIA PaCa-2 and MGEM6. The combination index (CI) was
calculated for each combination ratio by using the formula: CI¼ (D)
1/(Da)1 þ (D)2/(Da)2, in which (Da)1 and (Da)2 are the concen-
trations required for single agents to achieve a drug effect
(a ¼ 0.1e0.9), that means growth inhibition rate and (D)1 and (D)2
are the concentrations of gemcitabine and HU, respectively, used to
achieve the same effect. The CI value determines the effect of drug
combinations with <1, 1, and >1 indicating a synergistic, additive,
and antagonistic effect, respectively, since synergism and antago-
nism are deﬁned as greater (synergism) and less (antagonism) than
the expected additive effect, respectively (21).
2.10. Statistical analysis
The differences between the groups were analyzed using the
Student's t-test. A p value of <0.05 was considered signiﬁcant.
3. Results
3.1. Establishment of gemcitabine-resistant cells and the estimation
of drug resistance
After exposure to 1mg/mL ethyl methanesulfonate for 24 h, MIA
PaCa-2 cellswere cultured innormalmedium for 1week. Thereafter,
cells were selected using media containing subsequently 10 and
100 nM gemcitabine for 1 week and 2 weeks, respectively. Twelve
colonies were isolated after the selection process. Two clones,
namedMGEM6 andMGEM8, were cultured in 100 nM gemcitabineTable 1
The sensitivity of gemcitabine-resistant cells to the anticancer agents tested. The IC50 valu
resistance) is the ratio that IC50 for the cells divided by IC50 for MIA PaCa-2 cells. * indic
Agents Gemcitabine
Cells IC50 RR
MIAPaCa-2 6.9 ± 0.7
MGEM6 465.9 ± 26.7 67.8*
MGEM8 230.5 ± 12.0 33.0*
MGEM6/CNT1#17 171.0 ± 16.6 24.9*
MGEM6/CNT1#19 80.1 ± 4.4 11.7*
MGEM6/KD5-6 3.7 ± 0.6 0.5
MGEM6/CNT1#17KD5-7 3.1 ± 0.3 0.5containing DMEMwith 10% FCS and used for further analyses, since
these clones showed a growth comparativewith that of the parental
cells. We performed a survival assay in the presence of gemcitabine
and found that compared to the parental cells, MGEM6 andMGEM8
cells were 67.8- and 33.0-fold more resistant to gemcitabine,
respectively (Table 1). MGEM6 andMGEM8 cells were also resistant
to Ara-C and cladribine, although to a lesser extent.
3.2. Gemcitabine accumulation was decreased in gemcitabine-
resistant cells
First, we examined gemcitabine and its phosphorylated forms
accumulation in the gemcitabine-resistant and parental cells. The
concentration of gemcitabine in the resistant cells was about one
third of that in the parental cells (Fig. 1A).
To understand the mechanism underlying the low gemcitabine
and its derivatives accumulation in the resistant cells, we evaluated
the efﬂux gemcitabine and its probable phosphorylated derivatives
from gemcitabine efﬂux of these cells and found that it was com-
parable with that of the parental cells (Fig. 1B). From these data, we
expected that the gemcitabine uptake would be decreased in
MGEM6 and MGEM8 cells.
3.3. Gemcitabine accumulation was decreased owing to the
attenuation of CNT1 expression
Cellular uptake of gemcitabine has been reported to be mainly
mediated by CNT1, ENT1, and ENT2 (22). To identify the trans-
porters responsible for the low gemcitabine uptake, we evaluated
the gemcitabine accumulation under inhibitory conditions for the
nucleoside transporter(s) CNT1, ENT1, and/or ENT2. In the absence
of Na ions, the gemcitabine accumulation dramatically decreased in
the parental cells but not in the MGEM6 and MGEM8 cells
compared with that in the presence of these ions (Fig. 1C). These
data indicate that the gemcitabine uptake by the sodium-
dependent uptake transporter CNT1 was decreased in MGEM6
and MGEM8 cells. The uptake of gemcitabine by ENT2 was lower in
the gemcitabine-resistant cells than in the parental cells. As shown
by immunoblotting, the expression of CNT was clearly decreased in
MGEM6 and MGEM8 cells; the expression of ENT2, however, was
comparable with that of the parental cells (Fig. 2).
3.4. CNT1 overexpression sensitized the gemcitabine-resistant cells
to gemcitabine
To determine whether the decrease in gemcitabine uptake was
correlated with the gemcitabine resistance, we transfected MGEM6
cellswithCNT1. The expressionof CNT1washighly increased inCNT1-
transfected,MGEM6/CNT1#17, andMGEM6/CNT1#19 cells compared
with that in MIA PaCa-2 and MGEM6 cells (Fig. 2A). Gemcitabine
sensitivity was 3e6-fold higher in CNT1-transfected MGEM6 cells
than in MGEM6 cells (Table 1). Although the level of gemcitabinees aremeans ± SD from triplicate determinations by using the MTTassay. RR (relative
ates statistical signiﬁcance (p < 0.05).
Ara-C Cladribine
IC50 RR IC50 RR
0.93 ± 0.09 12.65 ± 2.75
1.39 ± 0.09 1.50* 48.73 ± 1.01 3.85*
7.37 ± 0.68 7.96* 59.90 ± 1.24 4.73*
1.90 ± 0.27 2.05* 29.10 ± 1.75 2.30*
ND ND
0.32 ± 0.06 0.34 1.60 ± 0.04 0.13
0.20 ± 0.03 0.22 1.27 ± 0.32 0.10
A B
C
Fig. 1. The intracellular gemcitabine concentration and the efﬂux of gemcitabine from gemcitabine-resistant cells. The intracellular concentrations of gemcitabine were evaluated
using [3H] gemcitabine. A. Gemcitabine accumulation was lower in the gemcitabine-resistant cells than in the parental cells. The intracellular accumulation of gemcitabine in each
cell line is shown (pmol/cell). B. Gemcitabine efﬂux from the gemcitabine-resistant cells was comparable with that of the parental cells. After incubation with gemcitabine, the time-
dependent change in the intracellular gemcitabine concentration was estimated as the efﬂux of gemcitabine. The x-axis represents time (min) and the y-axis represents the ratio of
the intracellular gemcitabine accumulation at the indicated time to that at time zero (%). The open circles denote MIA PaCa-2 cells and the closed square and the closed triangle
denote MGEM6 and MGEM8 cells, respectively. C. Gemcitabine accumulation of each cell line under normal and inhibitory conditions. Black box: incubation with HEPES-buffered
Ringer's solution, dark gray box: Na-free CNT1 transport inhibiting condition, light grey box: Na-free buffer containing 100 nM NBTI for the CNT1 and ENT1 transport inhibiting
condition, white box: Na-free buffer containing 10 mM dipyridamole for the CNT1, ENT1, and ENT2 transport inhibiting conditions. Data are means ± SD from triplicate studies.
A B
Fig. 2. CNT1 overexpression increased gemcitabine accumulation of gemcitabine resistant cells. A. Immunoblotting of nucleoside transporters. Membrane fractions (100 mg) of MIA
PaCa-2, MGEM6, MGEM8, MGEM6CNT1#17, and MGEM6CNT1#19 cells were separated by 7.5% SDS-PAGE and transferred to polyvinyl diﬂuoride (PVD) membranes. The hCNT1,
hENT1, hENT2 and Naþ/Kþ ATPase a3 proteins were detected with speciﬁc antibodies, and the immunoreactive bands were visualized using chemiluminescence and were exposed
to X-ray ﬁlm. The quantiﬁed intensities were indicated below the bands as the values normalized by the intensity of Naþ/Kþ ATPase a3 bands. B. Gemcitabine accumulation under
normal and inhibitory conditions. A. The intracellular gemcitabine accumulation in MIA PaCa-2, MGEM6 and MGEM6CNT1#17 was determined as described in the Materials and
Methods using [3H] gemcitabine.
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parental cells with an increase in CNT1-dependent uptake (Fig. 2B),
MGEM6/CNT1#17 cells were still highly resistant to gemcitabine
(Table 1). These data suggest that other mechanisms could have
contributed to the gemcitabine-resistant phenotype of these cells.3.5. RRM1 overexpression was associated with gemcitabine
resistance
A high expression of RRM1 and/or ribonucleotide reductase
small subunit (RRM2) have/has been reported to be related to
gemcitabine resistance (12). We therefore examined RRM1, RRM2,
and p53R2 expression in our cell lines. RRM1 expression was more
than 10-fold higher in MGEM6 and MGEM8 cells than in the
parental cells (Fig. 3A); the expression of RRM2 decreased slightly
and p53R2 was comparable (Fig. 3A).
To assess whether the high expression of RRM1 was associated
with gemcitabine resistance, RRM1 expression in MGEM6 and
MGEM6/CNT1#17 cells was knocked-down using shRNA and was
largely reduced inMGEM6/KD5-6 andMGEM6/CNT1#17KD5-7 cells
compared with that in MGEM6 cells, as shown by immunoblotting
(Fig. 3B). Furthermore, RRM1-silencedMGEM6,MGEM6/KD5-6, and
MGEM6/CNT1#17KD5-7 cells, and RRM1-silenced and CNT1-
overexpressing MGEM6 cells were more sensitive to gemcitabine
than MGEM6 cells were (Table 1). MGEM6/KD5-6 cells were asA B
D
Fig. 3. The gemcitabine accumulation and the expression of nucleoside transporters increa
lysates (20 mg) of the indicated cell lines were separated by 7.5% SDS-PAGE, and each protein
the bands as the values normalized by the intensity of GAPDH. B. Immunoblotting of RRM1
MGEM6/KD5-6 and MGEM6/CNT1#17KD5-7 cells. C. Gemcitabine accumulation in RRM1-s
silenced cells were determined as described in Materials and Methods using [3H] gemcit
cells. The mRNA expressions of nucleoside transporters were evaluated of the indicated ce
expression in MGEM6 cells. E. Immunoblotting of nucleoside transporters in MIA PaCa-2
examined by immunoblotting as described above. The quantiﬁed intensities were indicated bsensitive to gemcitabine as the parental andMGEM6/CNT1#17KD5-
7 cells were, although CNT1 expression in MGEM6/KD5-6 cells was
expected to be lower than that in the parental cells and similar to
that in MGEM6, since we didn't manipulate CNT1 expression of
MGEM6/KD5-6 cells directly (Table 1).
To clarify the RRM1 knockdown effect on gemcitabine accu-
mulation, we estimated the intracellular gemcitabine concentra-
tion and the expression of nucleoside transporters. We found that
the gemcitabine concentration was much higher in MGEM6/KD5-6
than in MGEM6 cells (Fig. 3C). Furthermore, the expression of CNT1,
ENT1, and ENT2 mRNA was increased compared with that in
MGEM6 cells (Fig. 3D). As shown by immunoblotting, the expres-
sion of CNT1 was clearly increased in MGEM6/KD5-6 cells (Fig. 3E).
These data indicate that the knockdown of RRM1 could not only
reduce RRM1 expression but also increase gemcitabine accumula-
tion by increasing the expression of uptake transporters. In addi-
tion, the knockdown of RRM1made MGEM6 cells more sensitive to
Ara-C and cladribine than the parental cells were (Table 1).3.6. The inhibition of RRM1 activity can overcome gemcitabine
resistance
To understand whether the inhibition of RR activity could
enhance the gemcitabine cytotoxic activity, we examined the
sensitivity of the cells to gemcitabine in the presence of a non-toxicC
E
sed in RRM1-silenced cells. A. Immunoblotting of RRM1, RRM2, and p53R2. Total cell
was detected with speciﬁc antibodies. The quantiﬁed intensities were indicated below
in RRM1-silenced cells. ShRNA effectively knocked down RRM1 protein expression in
ilenced cells. Intracellular gemcitabine concentrations of the indicated cells in RRM1-
abine. D. q-PCR of nucleoside transporter expression in MGEM6 and MGEM6/KD5-6
lls. Their expressions were indicated with the arbitrary unit as standardized with the
, MGEM6, and MGEM6/KD5-6 cells. The expression of nucleoside transporters were
elow the bands with the values normalized by the intensity of Naþ/Kþ ATPase a3 band.
Table 2
The sensitivity of the cells to gemcitabine in the presence of nontoxic dose of HU.
IC50 values are means ± SDs from triplicate determination with MTT assay in the
absence and presence of HU (100 mM). RRmeans relative resistance. RR is the ratio of
IC50 for each cell divided by IC50 for MIAPaCa-2 cells. * indicates statistically sig-
niﬁcant (P < 0.05).
Agents Gemcitabine Gemcitabine þ HU
Cells IC50 RR IC50 RR
MIAPaCa-2 6.1 ± 0.2 5.7 ± 0.1
MGEM6 644.7 ± 33.5 105.8* 338.9 ± 54.0 59.6*
MGEM8 178.3 ± 3.0 29.2* 111.4 ± 2.0 19.6*
K. Minami et al. / Journal of Pharmacological Sciences 127 (2015) 319e325324concentration (100 mM) of the RRM2 inhibitor HU. HU enhanced
the gemcitabine cytotoxicity against MGEM6 and MGEM8 cells
about 1.5 fold (Table 2). Next, we evaluated whether HU synergis-
tically enhanced the effect of gemcitabine. The CI values forMGEM6
cells were less than 1.0 in any of the affected fractions (Fig. 4),
which indicates cell survival ratios, while those for MIA PaCa-2 cells
were 1.0. We therefore showed a synergistic effect of the combi-
nation of gemcitabine and HU only on the gemcitabine-resistant
cells (Fig. 4).4. Discussion
Although gemcitabine is a valuable anticancer agent, drug
resistance proves to be a large obstacle for successful cancer
chemotherapy. Several molecular changes, the attenuation of the
expression of the nucleoside uptake transporters CNT1, ENT1, and
ENT2, a change in the expression of the cytidinemetabolic enzymes
deoxycytidine kinase (DCK) and cytidine deaminase, the over-
expression of the nucleotide metabolic enzymes RRM1 and RRM2,
and an increase in the expression of the efﬂux transporters ABCC5
and ABCC10 have been reported to underlie gemcitabine resistance
(3e14). At least some of these proteins are thought to inﬂuence
each other, since almost all of them are involved in nucleic acid
homeostasis.
In the present study, we established gemcitabine-resistant cells
and found that the cells have two mechanisms underlying their
gemcitabine resistance. The accumulation data obtained from the
nucleoside transporter function inhibition experiments showed
that gemcitabine uptake by CNT1 and ENT2 was decreased in the
gemcitabine-resistant cells compared with that in the parental
cells. In contrast, ENT2 expression inMGEM6 andMGEM8 cells was
comparable with that in the parental cells as shown by immuno-
blotting. ENT2-dependent substrate uptake might be regulated at a
functional level since disrupted plasma membrane localization ofFig. 4. CI values of gemcitabine and HU. The graphs show the CI values within a range of 0.1ENT2 was previously reported to be related to gemcitabine resis-
tance (5).
Not only CNT1 but also CNT3 has been reported to transport
gemcitabine (23,24). The effect of CNT3 on gemcitabine resistance
in the cells was thought to be marginal since we could not detect
CNT3mRNA by using RT-PCR (data not shown); however, we found
a clear decrease in CNT1 protein expression. RRM1 has been
recognized as a tumor suppressor gene from a study on the
involvement of chromosome 11 in non-small cell lung cancer and
Wilms' tumor (25,26). However, it has been controversial whether
RRM1 is a favorable or poor prognosis factor (27e29). The gemci-
tabine metabolite dFdCDP can inhibit RRM1 (30) and RRM1 over-
expression has been reported to play a role in gemcitabine
resistance (10,11). Indeed, we found that RRM1 overexpression is
one of the mechanisms underlying gemcitabine resistance in
MGEM6 cells. CNT1-transfected MGEM6 cells in which the gemci-
tabine accumulation was similar to that of the parental cells were
24-fold more resistant to gemcitabine than the parental cells were,
maybe because high amout of RRM1 can trap dFdCDP and block its
inhibitory activity of RR and dFdCTP synthesis. Only knockdown of
RRM1 sufﬁciently suppressed the gemcitabine resistance pheno-
type of MGEM6 cells. Although RRM1 kockdown induced mRNA of
nucleoside transports, only CNT1 protein increased (Fig. 3D, E).
These results suggested that ENT1 and ENT2 protein might be
regulated with unidentiﬁed posttranscriptional regulations. Since
in the cells with high RRM1 expression RRM1 can capture dFdCDP
and sustain RR activity, the nucleotide salvage pathway that acti-
vates gemcitabine is dispensable. Reversely, when RRM1 expres-
sion is decreased, dFdCDP can suppress RR activity and the de novo
pathway of dNTP synthesis (11). Under this condition, dFdCTP
concentration increases and effectively induces cell death since the
cancer cells are dependent on the salvage pathway for nucleotide
supply.
Our data support that suppression of RRM1 expression and/or
RR activity is a promising approach to overcome gemcitabine
resistance in RRM1-overexpressing tumors. However, since a much
higher concentration of a RRM1 inhibitor is needed to inhibit RR
activity for RRM1-overexpressing cells than for sensitive cells, such
a concentration will induce strong adverse effects to normal cells.
From this point of view, RRM2-speciﬁc or RR holoenzyme forma-
tion inhibitors might be practical and promising agents to enhance
the effect of gemcitabine. Although the effects of HU on RRM2were
reported to be small (31), in the present study we showed a syn-
ergistic effect between HU and gemcitabine only on the gemcita-
bine resistant cells. Unfortunately, we were unable to obtain some
other RR inhibitors than used in this study as they will be more
promising to overcome gemcitabine resistance (32, 33).e0.9, with increments of 0.1, of every affected fraction of MIA PaCa-2 and MGEM6 cells.
K. Minami et al. / Journal of Pharmacological Sciences 127 (2015) 319e325 325An increase in cytidine deaminase and a decrease in DCK are
two other mechanisms underlying gemcitabine resistance,
although their respective increase and decrease limit the nucleo-
tide supply from the salvage pathway. Interestingly, however, when
RR activity is effectively inhibited, cancer cell growth is blocked
because of this low nucleotide supply. Whether the relationship
between gemcitabine and nucleotide metabolism in the
gemcitabine-resistant cells is correlated with the expression of
efﬂux transporters remains to be elucidated.
Here, we established gemcitabine-resistant cells with dual
resistance mechanisms and showed that the inhibition of RR is one
of the most logical and promising approaches to overcome gem-
citabine resistance.Conﬂict of interest
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